---
figid: PMC4259959__WJCO-5-990-g002
figtitle: Representation of the molecular crosstalk between estrogen receptor and
  the receptor tyrosine kinases and PI3K-Akt-mTOR axes
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC4259959
filename: WJCO-5-990-g002.jpg
figlink: /pmc/articles/PMC4259959/figure/F2/
number: F2
caption: 'A representation of the molecular crosstalk between estrogen receptor and
  the receptor tyrosine kinases and PI3K-Akt-mTOR axes. In breast cancer, the PI3K-Akt-mTOR
  pathway modulates responses to signals communicated through growth factor receptors
  and the estrogen receptor (ER), and this crosstalk is important for sensitivity
  to anti-endocrine therapy. In particular, Akt and ERK1/2 phosphorylate ER on key
  residues involved in the induction of ligand-independent activation of DNA transcription.
  Furthermore, the converse occurs: estradiol, bound to membrane ER, interacts with
  and activates a regulatory subunit of PI3K. The mammalian target of rapamycin (mTOR)
  signaling cascade is another key regulatory pathway that controls proliferation
  and survival in cancer cells and plays an important role in the molecular crosstalk
  with the ER pathway. Two mTOR-interacting proteins, raptor and rictor, define distinct
  branches of the mTOR pathway: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
  Both active mTORC1 (via the phosphorylation of downstream targets, such as 4E-BP1
  and p70S6 Kinase) and active mTORC2 contribute to promoting cellular survival and
  proliferation. EGF: Epidermal growth factor; IGF: Insulin-like growth factor; PDGF:
  Platelet derived growth factor; PI3K: Phosphatidylinositol-3-phosphate kinase; E2:
  Estradiol; IRS-1: Insulin receptor substrate-1; RAS–RAF–MEK–ERK: Mitogen activated
  protein kinase pathway; HSP90: Heat shock protein 90; PDK-1: Pyruvate dehydrogenase
  lipoamide kinase isozyme 1; p70S6K: Protein 70S6 kinase; 4EBP1: Eukaryotic translation
  initiation factor 4E-binding protein 1; ERE: Estrogen response element.'
papertitle: 'Overcoming endocrine resistance in metastatic breast cancer: Current
  evidence and future directions.'
reftext: Andrea Milani, et al. World J Clin Oncol. 2014 Dec 10;5(5):990-1001.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9581326
figid_alias: PMC4259959__F2
figtype: Figure
redirect_from: /figures/PMC4259959__F2
ndex: 1b153bdb-ded8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4259959__WJCO-5-990-g002.html
  '@type': Dataset
  description: 'A representation of the molecular crosstalk between estrogen receptor
    and the receptor tyrosine kinases and PI3K-Akt-mTOR axes. In breast cancer, the
    PI3K-Akt-mTOR pathway modulates responses to signals communicated through growth
    factor receptors and the estrogen receptor (ER), and this crosstalk is important
    for sensitivity to anti-endocrine therapy. In particular, Akt and ERK1/2 phosphorylate
    ER on key residues involved in the induction of ligand-independent activation
    of DNA transcription. Furthermore, the converse occurs: estradiol, bound to membrane
    ER, interacts with and activates a regulatory subunit of PI3K. The mammalian target
    of rapamycin (mTOR) signaling cascade is another key regulatory pathway that controls
    proliferation and survival in cancer cells and plays an important role in the
    molecular crosstalk with the ER pathway. Two mTOR-interacting proteins, raptor
    and rictor, define distinct branches of the mTOR pathway: mTOR complex 1 (mTORC1)
    and mTOR complex 2 (mTORC2). Both active mTORC1 (via the phosphorylation of downstream
    targets, such as 4E-BP1 and p70S6 Kinase) and active mTORC2 contribute to promoting
    cellular survival and proliferation. EGF: Epidermal growth factor; IGF: Insulin-like
    growth factor; PDGF: Platelet derived growth factor; PI3K: Phosphatidylinositol-3-phosphate
    kinase; E2: Estradiol; IRS-1: Insulin receptor substrate-1; RAS–RAF–MEK–ERK: Mitogen
    activated protein kinase pathway; HSP90: Heat shock protein 90; PDK-1: Pyruvate
    dehydrogenase lipoamide kinase isozyme 1; p70S6K: Protein 70S6 kinase; 4EBP1:
    Eukaryotic translation initiation factor 4E-binding protein 1; ERE: Estrogen response
    element.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - IRS1
  - HSP90AA1
  - HSP90B1
  - TRAP1
  - HSP90AB1
  - PDK1
  - PDPK1
  - PDK2
  - PDK3
  - PDK4
  - KRAS
  - HRAS
  - NRAS
  - AKT1
  - AKT2
  - AKT3
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - RPTOR
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RPS6KB1
  - RPS6KB2
  - EIF4EBP1
  - EPHB2
  - MAPK1
  - MAPK3
  - Egfr
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Hsp83
  - Gp93
  - Pdk1
  - Pdk
  - ras
  - Ras64B
  - Ras85D
  - Akt
  - Raf
  - Crtc
  - Dsor1
  - Mtk
  - S6k
  - Thor
  - Erk7
  - rl
  - Estrogen
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
